Design Therapeutics Inc
NASDAQ:DSGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Design Therapeutics Inc
NASDAQ:DSGN
|
US |
|
Hannan Metals Ltd
XTSX:HAN
|
CA |
Intrinsic Value
The intrinsic value of Design Therapeutics Inc (DSGN) under the Base Case is 0.95 USD per share.
Compared with the current market price of 10.64 USD, the stock appears
Overvalued by 91% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Design Therapeutics Does
Design Therapeutics is a biotechnology company developing medicines for inherited diseases caused by toxic repeat expansions in DNA. Its main idea is to use small molecules, not gene editing or protein drugs, to target the root cause of these disorders. The company’s lead programs have focused on neuromuscular and nervous system diseases such as myotonic dystrophy and Friedreich ataxia.
- Headquarters
- United States of America US
- Employees
- 54
- IPO date
- Mar 26, 2021
Earnings Waterfall
Design Therapeutics Inc
The intrinsic value for Design Therapeutics Inc (DSGN) under the Base Case is 0.95 USD.
Compared with the current market price of 10.64 USD, the stock appears Overvalued by 91% .